Press "Enter" to skip to content

Moderna vaccine shows 94.1% efficacy in trial: Study

Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna’s Covid-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study.
Translate »